Identification of Prognostic Factors and New Therapeutic Targets in Cutaneous Lymphomas (LYMPHOTEQ)

Assistance Publique - Hôpitaux de Paris

Status: Not yet enrolling

Conditions: Cutaneous Lymphoma

Treatments: Other: Biologic Samples

Study type: Interventional

Funder types: Other

Identifiers

NCT04520529

APHP190179

Details and patient eligibility

About

Cutaneous lymphomas are a heterogeneous group of extra-nodal lymphomas. The prognosis of cutaneous lymphomas is extremely variable from one subject to another. In the majority of cases, there is no cure for cutaneous lymphomas. Cutaneous lymphomas primarily affect the skin, and secondarily the blood, lymph nodes and possibly other organs. The discovery of new molecular prognostic factors will allow a better identification of patients at high risk of aggressive evolution and the implementation of a personalized therapeutic strategy. The identification of new therapeutic targets is necessary in order to develop new innovative treatments for cutaneous lymphomas.The primary objective is to identify novel molecular prognostic factors associated with 5-year overall survival in cutaneous lymphoma.

Enrollment: 500 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age> 18 years old
• Informed consent signed by the patient
• Suspicion of primary cutaneous lymphoma or confirmed lymphoma according to WHO/ISCL/EORTC criteria

Exclusion criteria

• Patient under guardianship or curatorship
• Lack of affiliation to social security

Trial design

Primary purpose: Other

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

500 participants in 1 patient group

Patients with primary cutaneous lymphoma

Other group

Treatment:

Other: Biologic Samples